US Patent Issued to The Board of Trustees of the Leland Stanford Junior University on June 3 for "Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells" (California Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,318,448, issued on June 3, was assigned to The Board of Trustees of the Leland Stanford Junior University (Stanford, Calif.).

"Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells" was invented by Irving L. Weissman (Stanford, Calif.), Mingye Feng (Mountain View, Calif.) and Jens-Peter Volkmer (Menlo Park, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contac...